Deutsche Bank AG Makes New Investment in PROCEPT BioRobotics Corporation $PRCT

Deutsche Bank AG bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 248,483 shares of the company’s stock, valued at approximately $5,611,000.

Other large investors also recently bought and sold shares of the company. Alliancebernstein L.P. grew its holdings in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in PROCEPT BioRobotics by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after acquiring an additional 1,218,815 shares during the last quarter. Mackenzie Financial Corp raised its stake in PROCEPT BioRobotics by 8.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after acquiring an additional 118,971 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in PROCEPT BioRobotics by 11.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock worth $47,841,000 after acquiring an additional 155,601 shares during the period. Finally, State Street Corp lifted its position in PROCEPT BioRobotics by 12.4% during the 4th quarter. State Street Corp now owns 1,489,029 shares of the company’s stock worth $46,845,000 after acquiring an additional 164,358 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: The lawsuit covers investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors may apply to serve as lead plaintiff, while any potential recovery would be handled through a contingency-fee arrangement. DJS Law Group lawsuit notice
• Negative Sentiment: The complaints allege PROCEPT misled investors about sales performance and inventory conditions, including weaker-than-expected unit handpiece sales, excess customer inventory, channel stuffing, and late-quarter bulk discounts. These allegations have not been proven in court but could raise litigation costs, create potential liabilities, and damage investor confidence. Hagens Berman investor alert
• Negative Sentiment: Kahn Swick & Foti said the alleged inventory issues contributed to an approximately 18% share-price decline during the relevant period. The repeated notices from Rosen, Kaplan Fox, SBS, Levi & Korsinsky, and other firms reinforce the negative legal narrative surrounding PROCEPT. Kahn Swick & Foti lawsuit notice

PROCEPT BioRobotics Stock Down 2.0%

Shares of PRCT opened at $21.25 on Tuesday. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $42.43. The stock’s 50 day moving average is $20.37 and its two-hundred day moving average is $24.11. The firm has a market cap of $1.22 billion, a P/E ratio of -10.95 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same quarter in the prior year, the company posted ($0.35) earnings per share. The business’s revenue was up 19.3% on a year-over-year basis. Analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Truist Financial set a $21.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Citigroup lowered shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. Finally, Piper Sandler reduced their target price on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.00.

Insiders Place Their Bets

In related news, CEO Larry L. Wood bought 23,900 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the acquisition, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 1,000 shares of company stock worth $28,480 in the last quarter. Insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.